CTOs on the Move


 
We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.89bio.com
  • 535 Mission Street 14th Floor
    San Francisco, CA USA 94105
  • Phone: 212.520.2765

Executives

Name Title Contact Details

Funding

89bio raised $60M on 10/25/2018
89bio raised $83.8M on 07/14/2020

Similar Companies

Spotlight Therapeutics

Spotlight Therapeutics is a venture funded early-stage biotechnology company with a mission to develop a new class of therapeutics by enabling direct in vivo gene editing. Founded by Alex Marson (UCSF), Jacob Corn (UC Berkeley), and Patrick Hsu (Salk Institute) in December of 2017, Spotlight is building its core technology platform to achieve precise in vivo gene editing in targeted cell populations. With a therapeutic focus centered on oncology, our engineered nucleases edit the genes in targeted disease organs thereby inactivating or altering the gene product. We are hiring rapidly to build out our cutting-edge research and development team. This team is responsible for preclinical development ranging from protein engineering, gene editing to immuno-oncology and in vivo safety studies. Join us and work on the next generation of gene editing therapeutics in a fast-paced and exciting environment.

Nano Mark

Nano Mark, Llc is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Tactile

Medical Tactile is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Peptilogics

Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics` lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.

Response Genetics

Response Genetics is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.